These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11225991)

  • 1. Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant.
    Hilburger Ryan M; Abrams SI
    Cancer Immunol Immunother; 2001 Jan; 49(11):603-12. PubMed ID: 11225991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific CD8(+) CTL reactive against tumor cells expressing a naturally occurring rejection epitope.
    Ryan MH; Bristol JA; McDuffie E; Abrams SI
    J Immunol; 2001 Oct; 167(8):4286-92. PubMed ID: 11591751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides.
    Bertholet S; Iggo R; Corradin G
    Eur J Immunol; 1997 Mar; 27(3):798-801. PubMed ID: 9079825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
    Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
    J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells.
    Yanuck M; Carbone DP; Pendleton CD; Tsukui T; Winter SF; Minna JD; Berzofsky JA
    Cancer Res; 1993 Jul; 53(14):3257-61. PubMed ID: 7686815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.
    Abrams SI; Stanziale SF; Lunin SD; Zaremba S; Schlom J
    Eur J Immunol; 1996 Feb; 26(2):435-43. PubMed ID: 8617315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants.
    Hoffmann TK; Nakano K; Elder EM; Dworacki G; Finkelstein SD; Appella E; Whiteside TL; DeLeo AB
    J Immunol; 2000 Nov; 165(10):5938-44. PubMed ID: 11067956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes.
    Johnston JV; Malacko AR; Mizuno MT; McGowan P; Hellström I; Hellström KE; Marquardt H; Chen L
    J Exp Med; 1996 Mar; 183(3):791-800. PubMed ID: 8642283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.
    Vierboom MP; Nijman HW; Offringa R; van der Voort EI; van Hall T; van den Broek L; Fleuren GJ; Kenemans P; Kast WM; Melief CJ
    J Exp Med; 1997 Aug; 186(5):695-704. PubMed ID: 9271585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased frequencies of CD8+ T lymphocytes recognizing wild-type p53-derived epitopes in peripheral blood correlate with presence of epitope loss tumor variants in patients with hepatocellular carcinoma.
    Cicinnati VR; Zhang X; Yu Z; Ferencik S; Schmitz KJ; Dworacki G; Kaczmarek E; Oldhafer K; Frilling A; Baba HA; Schmid KW; Grosse-Wilde H; Broelsch CE; DeLeo AB; Gerken G; Beckebaum S
    Int J Cancer; 2006 Dec; 119(12):2851-60. PubMed ID: 16998881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between CD8 dependency and determinant density using peptide-induced, Ld-restricted cytotoxic T lymphocytes.
    Alexander MA; Damico CA; Wieties KM; Hansen TH; Connolly JM
    J Exp Med; 1991 Apr; 173(4):849-58. PubMed ID: 1901079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of human p53-overexpressing tumor cells by an HLA A*0201-restricted murine T-cell receptor expressed in Jurkat T cells.
    Liu X; Peralta EA; Ellenhorn JD; Diamond DJ
    Cancer Res; 2000 Feb; 60(3):693-701. PubMed ID: 10676655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.
    Umano Y; Tsunoda T; Tanaka H; Matsuda K; Yamaue H; Tanimura H
    Br J Cancer; 2001 Apr; 84(8):1052-7. PubMed ID: 11308253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes.
    Blake J; Johnston JV; Hellström KE; Marquardt H; Chen L
    J Exp Med; 1996 Jul; 184(1):121-30. PubMed ID: 8691125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of transgenic mice to generate high affinity p53 specific cytolytic T cells.
    Yu Z; Liu X; McCarty TM; Diamond DJ; Ellenhorn JD
    J Surg Res; 1997 May; 69(2):337-43. PubMed ID: 9224403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL.
    Vierboom MP; Bos GM; Ooms M; Offringa R; Melief CJ
    Int J Cancer; 2000 Jul; 87(2):253-60. PubMed ID: 10861484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo.
    Tüting T; DeLeo AB; Lotze MT; Storkus WJ
    Eur J Immunol; 1997 Oct; 27(10):2702-7. PubMed ID: 9368629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases.
    Caldwell SA; Ryan MH; McDuffie E; Abrams SI
    J Immunol; 2003 Sep; 171(5):2402-12. PubMed ID: 12928387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant.
    McArdle SE; Rees RC; Mulcahy KA; Saba J; McIntyre CA; Murray AK
    Cancer Immunol Immunother; 2000 Oct; 49(8):417-25. PubMed ID: 11043848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells.
    Lacabanne V; Viguier M; Guillet JG; Choppin J
    Eur J Immunol; 1996 Nov; 26(11):2635-9. PubMed ID: 8921949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.